Publications
Publications
- March 2002 (Revised May 2002)
- HBS Case Collection
Genzyme: Engineering the Market for Orphan Drugs
Abstract
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures.
Keywords
Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Pharmaceutical Industry
Citation
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)